Skip to content
Clinical Trials – home
Verifiedinfo

NZOZ Wrocławskie Centrum Alzheimerowskie

Poland ul. Sikorskiego 7GHJ, 53-659 Wroclaw, Poland

  • 3 trials recruiting
  • Dementia Alzheimer's type · Agitation · Cognitive disorder
  • Adult patients

About Specializations

NZOZ Wrocławskie Centrum Alzheimerowskie in Wroclaw, Poland specialises in clinical trials of conditions such as Dementia Alzheimer's type, Agitation, Cognitive disorder, and other specialisations. This site conducts important research.

Main research areas of the site

Nervous System Diseases and Alzheimer’s Disease Research

At NZOZ Wrocławskie Centrum Alzheimerowskie in Wroclaw, clinical trials are focused on Nervous System Diseases, with a strong emphasis on Alzheimer disease, mild cognitive impairment, and related neurocognitive disorders. The studies are designed to test new treatment options, assess safety, and measure whether therapies can slow cognitive decline or improve daily functioning.

  • Evaluating new approaches for early Alzheimer’s disease and biomarker-defined patient groups
  • Studying treatments aimed at improving memory, thinking skills, and overall cognition
  • Assessing therapies for mild cognitive impairment and early dementia linked to Alzheimer’s disease

The site’s research portfolio reflects a clear focus on neurodegenerative diseases and the search for better ways to detect, manage, and treat progressive brain disorders.

Early-Stage Alzheimer’s Disease Treatment Studies

A major part of the research at this site involves therapies for early symptomatic Alzheimer’s disease and prodromal Alzheimer’s disease. These trials explore whether investigational treatments can preserve cognition, reduce disease progression, and support functional abilities in people at the earliest stages of illness.

  • Testing treatments intended to slow decline in early Alzheimer’s disease
  • Measuring effects on cognition and daily function
  • Exploring options for patients with biomarkers linked to disease activity

These studies help build evidence for future care strategies in Alzheimer’s disease, where early intervention may be especially important.

Biomarker-Driven Research in Neurodegenerative Diseases

The site also participates in research that looks beyond symptoms to the biological changes associated with Alzheimer’s disease. This includes studies examining amyloid accumulation, tau pathology, and inflammation-related markers to better understand how treatments may affect the underlying disease process.

  • Investigating therapies for patients with brain biomarkers linked to disease progression
  • Studying changes in amyloid and tau as indicators of treatment response
  • Supporting more precise research in neurodegenerative disorders

This area of work is important for improving diagnosis and identifying which patients may benefit most from emerging therapies.

Research on Dementia Symptoms and Behavioral Changes

Another important theme at NZOZ Wrocławskie Centrum Alzheimerowskie is the study of symptoms that affect quality of life in Alzheimer’s disease dementia, including agitation. These trials aim to find safer and more effective ways to manage behavioral symptoms alongside cognitive decline.

  • Evaluating treatments for agitation in Alzheimer’s disease
  • Focusing on symptom relief in Alzheimer’s disease dementia
  • Supporting care approaches that improve comfort and daily well-being

By addressing both cognitive and behavioral aspects of illness, the site contributes to broader dementia research and patient-centered care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
ul. Sikorskiego 7GHJ53-659 WroclawPoland
Recruiting now
3 trials
Conditions studied
3
Partner status
Verified

More sites in WroclawPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

11 clinical trials

Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dextromethorphan Hydrobromide
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:VHB937
  • Sponsor:Novartis Pharma AG
Countries:PolandPoland
  • Participants:65+ years
  • Substances:(3-BENZYL-3-METHYL-2,3-DIHYDROBENZOFURAN-6- YL)(PIPERIDIN-1-YL)METHANONE
  • Sponsor:Neurotherapia Inc.
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S
Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Donanemab
  • Sponsor:Eli Lilly & Co.
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S
Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tertomotide
  • Sponsor:Gemvax & Kael Co. Ltd.
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bepranemab
  • Sponsor:UCB Biopharma
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)
  • Sponsor:Alector LLC
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.